Why Biotech Fundraising Fails: 7 Commercial Gaps That Can Reduce Investor Confidence

Most biotech founders can talk about their science for an hour without notes. Ask the same team how many patients will realistically be treated in year three, who is paying for them, and what happens to the model if launch slips by a year, and the room tends to go quiet. That pause is where many raises start to wobble. Investors rarely pass because the biology is weak. They pass because the commercial story cannot carry the weight of the ask. This guide walks through seven commercial gaps that regularly erode investor confidence during capital raising, and explains how fundraising consulting services can help a team find and close them before the first pitch meeting.
Why Investor Confidence Is Harder to Earn Right Now
Money is available in biotech, but it is selective. J.P. Morgan's Q3 2026 Biopharma Licensing and Venture Report shows venture funding of $6.7 billion in the third quarter, down from $9.9 billion in the second, with $23.9 billion raised across 385 rounds so far this year. The same report notes that biopharma IPOs have raised $7.5 billion across 22 offerings, so the window is open for companies that look ready for it.
For younger companies the picture is tighter. Fierce Biotech reported, drawing on J.P. Morgan's first-quarter data, that 50 seed and Series A deals worth $2.3 billion closed in the first three months of 2026, against 60 deals worth $3.7 billion a year earlier. BioSpace's coverage of J.P. Morgan's 2025 analysis adds that seed and Series A rounds fell from 228 in 2024 to 191 in 2025, with heavier diligence and longer decision timelines.
Investors also know how hard the road is. BIO, Informa Pharma Intelligence and QLS Advisors found that candidates entering Phase I between 2011 and 2020 had a 7.9 percent likelihood of approval, and that reaching approval takes about 10.5 years on average. When the odds are that long, backers look hard for any sign that the team understands what happens after the science works.
What Fundraising Consulting Services Actually Cover for Biotech Teams
The term can sound like a polite way of saying "pitch deck help", so it is worth being precise. Fundraising consulting services, in a biotech setting, are the structured work of stress-testing the commercial case, tightening the financial model and shaping the narrative so that it survives investor diligence. The aim is not to dress up a weak plan. It is to find out where the plan is weak while there is still time to fix it.
Capital raising is the wider process: choosing the right investors, preparing materials, running meetings, handling diligence and closing the round. Consulting sits underneath that process and improves what goes into it. A company can have excellent investor introductions and still lose them in the second meeting if the commercial story does not hold together. The seven gaps below are the places where that most often happens.
Seven Commercial Gaps That Weaken a Biotech Raise
1. Market Assumptions That Start With a Big Number
The classic version goes like this: the disease affects two million people, the company only needs five percent, and that makes a very large business. It is tidy and almost always wrong. Real patients have to be diagnosed, referred to the right specialist, found eligible under the label and kept on treatment. Each step removes people, and experienced investors know it.
Forecasting history does not help the optimist. A study of 1,700 forecasts covering 260 drugs, summarised by IQVIA, found actual peak sales differing by 71 percent from predictions made a year before launch, with many forecasts overstating sales by more than 160 percent. A bottom-up model built on the real patient journey, with ranges instead of a single point, shows investors that the sceptical work has already been done.
2. A Commercial Plan That Stops at Approval
Many decks end with a regulatory milestone, as though approval and revenue were the same event. They are not. Investors want to know who will prescribe the product, what the launch will demand in medical affairs and sales, and whether the company plans to build that capability, partner for it or hand it to an acquirer. Each route changes what the equity is worth.
Nobody expects a final launch plan at Series A. They do expect a clear line of thinking and an honest account of what is still unknown. Vagueness reads as risk, and risk gets priced into the terms or into a polite no.
3. Pricing and Access Left for Later
Teams often treat price as something to settle after the pivotal data arrives. Investors treat it as part of the thesis. Payers decide whether a product reaches patients at all, and what they will want to see, whether comparative evidence, real-world outcomes or health-economic data, can shape trial design years in advance.
Even a rough view of likely pricing, coverage hurdles and the evidence payers expect in your target markets is far more convincing than silence. If the plan depends on a premium price, show who is expected to accept it and why.
4. A Competitor Slide That Ignores the Standard of Care
A table of pipeline competitors with the ticks conveniently in your favour is not a competitive analysis. The more useful question is what a physician or payer will do instead of choosing you. Often the answer is the existing standard of care, a cheaper generic, or simply waiting.
Investors with clinical or commercial backgrounds will test this within minutes. A team that has already mapped what must be true for its product to win, and how its programme will generate that evidence, comes across as one that understands the market it is entering, not just the molecule it is carrying.
5. A Financial Model Built to Reach a Number
A model that works backwards from the amount the company wants to raise, rather than forwards from the work that needs doing, is easy to spot. Revenue ramps are too steep, costs arrive too late, and the runway ends conveniently just after the next milestone. Investors may not say this out loud, but they will quietly discount everything else in the deck.
A credible model links spending to specific activities, shows base, downside and delayed-launch cases, and keeps its assumptions visible so an investor can change them and see what happens. This is where building the model around a fundable commercial story pays off, because the numbers and the narrative support each other instead of being written separately.
6. A Clinical Plan Disconnected From Commercial Evidence
Investors increasingly want to know what a data read-out will let the company do next, not only whether it will be positive. If a trial design satisfies regulators but not payers, prescribers or potential partners, the company can succeed scientifically and still struggle commercially.
Endpoints, comparators and patient selection all carry commercial consequences. Linking them early to what the market will need shows that clinical and commercial thinking are happening in the same room, which is exactly what a diligence team hopes to see.
7. A Funding Ask With No Milestone Logic
"We need $40 million to get through Phase II" is a statement, not a rationale. Investors want to know what the money buys: which milestones, over what period, with how much buffer, and what value those milestones unlock for the next round or a partner.
When the ask is not tied to inflection points, it looks like a request for runway rather than a plan, and the conversation drifts towards dilution. A tight use of proceeds that maps funds to milestones, and shows what happens if one slips, gives investors something specific to evaluate and, ideally, to back.
How to Close These Gaps Before You Approach Investors
Start by writing the commercial story on a single page: the patients, the path to market, who pays, why the product wins and what the money achieves. Then ask the science lead, the finance lead and the CEO to tell it separately. If three different stories come back, the raise is not ready, and it is far better to learn that in the boardroom than in a partner meeting.
Next, have someone with commercial experience from outside the team play a sceptical investor and ask the hardest questions. Do this months before the raise, not the week before. Rebuild the model with ranges and named assumptions, then make sure the data room, the deck and the model all tell the same story. None of this is glamorous, but with diligence timelines stretching, a consistent and well-tested case saves weeks that most teams cannot spare.
When It Makes Sense to Bring in Outside Help
Many teams handle early preparation internally, and that is often the right call. Outside support earns its fee when the round is large, when the team has deep scientific strength but limited commercial experience, or when an earlier raise stalled after investors questioned the market case.
When choosing an adviser, look for direct life sciences experience, a scope tied to a specific outcome and deliverables the team can keep using afterwards. Be cautious of anyone who leads with investor introductions in place of substance. The best advisers will challenge your assumptions, show their working and leave you better prepared for the next conversation.
How Illumination Strategy Supports Biotech Capital Raising
Illumination Strategy works with life sciences companies on the commercial foundations that investors look for. Our team helps founders test market assumptions, sharpen the path to commercialisation, build financial models that hold up in diligence and turn all of it into a story that investors can follow and repeat.
If a raise is coming in the next year, the best time to pressure-test the case is before the first meeting, while changes are still easy to make. Talk to our team about your next raise and we will help you work out where the story is strong and where it needs work.
Frequently Asked Questions
What are fundraising consulting services for biotech companies?
Fundraising consulting services help biotech companies prepare for investor scrutiny. The work typically covers market and commercial assessment, financial modelling, positioning and investor materials, so that the case holds up in diligence.
How is capital raising different from fundraising consulting?
Capital raising is the full process of approaching investors, running meetings, handling diligence and closing a round. Consulting improves the commercial case and materials that go into that process. The two work best together.
Why do biotech fundraises fail?
There is rarely one cause, but weak commercial foundations come up often. Unrealistic market assumptions, an unclear path to commercialisation, a loosely built financial model and a funding ask that is not tied to milestones all reduce investor confidence.
What do investors look for in a biotech commercial plan?
They look for a realistic patient funnel, a clear view of who pays and why, honest competitive positioning and a credible route to launch. They also want to see that the clinical plan will generate the evidence the market needs.
When should a biotech start preparing the commercial case for a raise?
As early as possible, and ideally six to twelve months before approaching investors. That leaves time to test assumptions, fix gaps and align the team around one story.
How detailed should a biotech financial model be for investors?
Detailed enough to link spending to specific activities and milestones, and simple enough that an investor can follow and challenge the assumptions. Base, downside and delayed-launch scenarios are more persuasive than a single optimistic case.
Do early-stage companies need a commercialisation plan?
Yes, although it can be high level. Investors do not expect a finished launch plan, but they do expect a clear view of the market, the likely route to patients and the main unknowns.

With nearly 30 years of life sciences leadership experience, Tim Glennon helps founders, executives, and investors navigate critical growth stages through commercialization strategy, market access, and scalable business planning.
Key Takeaways
- Investors rarely pass because the biology is weak; they pass when the commercial story cannot carry the ask.
- Early-stage funding has tightened, with fewer seed and Series A rounds and longer diligence.
- Seven common gaps include top-down market sizing, a plan that stops at approval, and pricing left for later.
- A credible model works forward from the work needed, with visible assumptions and multiple scenarios.
- Tie every dollar of the ask to milestones, and test the story with the team well before the raise.
More Insights
See how we’ve helped organizations achieve measurable commercialization success across industries.

CFRE vs. a Life Sciences Capital Raising Advisor: Who Do Biotech Founders Actually Need?
See the difference and who to hire for your biotech round. A certified fundraising executive raises donations; biotech needs capital-raising skills.

Why Biotech Fundraising Fails: 7 Commercial Gaps That Can Reduce Investor Confidence
Fundraising consulting services can expose the commercial gaps that weaken capital raising. See seven biotech fundraising weaknesses investors spot first.

Raising Capital for a Biotech Startup: What Investors Need to See Beyond a Pitch Deck
Capital raising for a biotech startup takes more than a pitch deck. Learn how commercial strategy, projections and milestones shape investor confidence.
.jpeg)
Capital Raising Mistakes Early-Stage Life Sciences Founders Make Before Series A
Seven capital raising mistakes life sciences founders make before Series A and how to avoid them, from Illumination Strategy's seed and bridge work.

